摘要
目的:评价疏风解毒胶囊和磷酸奥司他韦胶囊治疗成人流感样症状的经济性。方法:本研究采用前瞻性、实效临床试验设计方法,将流感样症状患者随机分为接受疏风解毒胶囊和磷酸奥司他韦胶囊治疗。由经过培训的调研员对患者进行随访,并收集成本和效果数据。以医疗卫生系统为研究角度,分别采用6个效果指标进行成本效果分析。结果:分别纳入接受疏风解毒胶囊和磷酸奥司他韦胶囊治疗的有效病例78例和72例。两组的48 h痊愈率(P=0.320)、48 h退热率(P=0.523)、48 h有效率(P=0.805)、5 d痊愈率(P=0.383)、5 d退热率(P=0.512)和5 d有效率(P=1.000)均无显著差异。疏风解毒胶囊组的门诊费用总额(P<0.01)和药品费用(P<0.01)显著低于磷酸奥司他韦胶囊组。结论:疏风解毒胶囊和磷酸奥司他韦胶囊治疗流感样症状的效果相当,疏风解毒胶囊成本低于磷酸奥司他韦胶囊,因此疏风解毒胶囊治疗流感样症状更具有经济性。
Objective： To evaluate the cost-effectiveness of Shufeng Jiedu capsules and oseltamivir phosphate capsules for adult patients with influenza-like illness（ILI）. Methods： Patients with ILI were randomized in a prospective pragmatic clinical trial to treatment group of either Shufeng Jiedu capsules or oseltamivir phosphate capsules and were followed up by trained investigators for collecting clinical and cost data. From the health care system perspective,six clinical effectiveness indicators were used for the cost-effectiveness analyses. Results：There were 78 and 72 patients in Shufeng Jiedu group and oseltamivir phosphate group respectively who were included in the final analyses. The remission rate,response rate and antipyretic effectiveness rate at 48 h or 5 d after treatment were not significantly different between the two groups. The total medical cost and drug expenses of Shufeng Jiedu capsules were lower than those of oseltamivir phosphate capsules（P〈0. 01）. Conclusion： Shufeng Jiedu capsules or oseltamivir phosphate capsules are similar in efficacy of treating adults with ILI,but the cost with Shufeng Jiedu capsules is lower. Shufeng Jiedu capsules is cost-effective in comparison with oseltamivir phosphate capsules for adult ILI.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第1期14-21,共8页
Chinese Journal of New Drugs
关键词
流感样症状
疏风解毒胶囊
磷酸奥司他韦胶囊
药物经济学评价
成本效果分析
influenza-like illness
Shufeng Jiedu capsules
oseltamivir phosphate capsules
economic evaluation
cost-effectiveness analysis
